APA (7th ed.) Citation

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., . . . Winer, E. P. (2018). Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Annals of Oncology, 29(7), 1541. https://doi.org/10.1093/annonc/mdy155

Chicago Style (17th ed.) Citation

Hortobagyi, G N., et al. "Updated Results from MONALEESA-2, a Phase III Trial of First-line Ribociclib Plus Letrozole Versus Placebo Plus Letrozole in Hormone Receptor-positive, HER2-negative Advanced Breast Cancer." Annals of Oncology 29, no. 7 (2018): 1541. https://doi.org/10.1093/annonc/mdy155.

MLA (9th ed.) Citation

Hortobagyi, G N., et al. "Updated Results from MONALEESA-2, a Phase III Trial of First-line Ribociclib Plus Letrozole Versus Placebo Plus Letrozole in Hormone Receptor-positive, HER2-negative Advanced Breast Cancer." Annals of Oncology, vol. 29, no. 7, 2018, p. 1541, https://doi.org/10.1093/annonc/mdy155.